Abstract 3574: Identification and preclinical characterization of CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase, in lymphoma and non-small cell lung cancer models

Small Cell ◽

Small Cell Lung ◽

Active Inhibitor ◽

Anaplastic Lymphoma ◽

Cancer Models ◽

Orally Active

Abstract A243: Characterization of NMS‐E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK‐dependent lymphoma and non‐small cell lung cancer models

10.1158/1535-7163.targ-09-a244 ◽

2009 ◽

Cited By ~ 14

Author(s):

Elena Ardini ◽

Maria Menichincheri ◽

Cristina De Ponti ◽

Nadia Amboldi ◽

Maria Beatrice Saccardo ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Molecule ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Cancer Models ◽

Molecule Inhibitor

Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)

Case Medical Research ◽

10.31525/ct1-nct04009317 ◽

2019 ◽

Author(s):

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

First Line Treatment

5P Targeted degradation of anaplastic lymphoma kinase by target degraducer in non-small cell lung cancer

Annals of Oncology ◽

10.1016/s0923-7534(21)00167-8 ◽

2016 ◽

Vol 27 ◽

pp. ix2

Author(s):

J.Y. Hwang ◽

C.-H. Park ◽

D.H. Lee ◽

C.H. Kang ◽

C.O. Lee ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Visual Effects in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Treated with Crizotinib

Annals of Oncology ◽

10.1016/s0923-7534(20)32041-x ◽

2012 ◽

Vol 23 ◽

pp. xi44

Author(s):

P.-C. Yang ◽

R. Salgia ◽

B. Solomon ◽

A.T. Shaw ◽

D.R. Camidge ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Visual Effects ◽

Anaplastic Lymphoma ◽

Alk Positive ◽

Nsclc Patients

Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer

Cancer Management and Research ◽

10.2147/cmar.s223441 ◽

2019 ◽

Vol Volume 11 ◽

pp. 9195-9202 ◽

Cited By ~ 3

Author(s):

Maobai Liu ◽

Longfeng Zhang ◽

Qishu Huang ◽

Na Li ◽

Bin Zheng ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Effectiveness Analysis ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis

Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer

Cancer Science ◽

10.1111/j.1349-7006.2011.01970.x ◽

2011 ◽

Vol 102 (8) ◽

pp. 1602-1604 ◽

Cited By ~ 9

Author(s):

Takashi Kijima ◽

Kengo Takeuchi ◽

Satoshi Tetsumoto ◽

Kazuki Shimada ◽

Ryo Takahashi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Fusion Type

PCN107 Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for NON-SMALL CELL LUNG Cancer in Greece

Value in Health ◽

10.1016/j.jval.2020.08.244 ◽

2020 ◽

Vol 23 ◽

pp. S442

Author(s):

G. Gourzoulidis ◽

O. Zisimopoulou ◽

N. Boubouchairopoulou ◽

C. Michailidi ◽

C. Almond ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Small Cell ◽

Small Cell Lung ◽

Anaplastic Lymphoma ◽

Effectiveness Analysis ◽

Previously Treated

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

New England Journal of Medicine ◽

10.1056/nejmx110006 ◽

2011 ◽

Vol 364 (6) ◽

pp. 588-588

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Kinase Inhibition ◽

Re‐Evaluating Progression in an Era of Progress: A Review of First‐ and Second‐Line Treatment Options in Anaplastic Lymphoma Kinase‐Positive Non‐Small Cell Lung Cancer

The Oncologist ◽

10.1634/theoncologist.2015-0396 ◽

2016 ◽

Vol 21 (6) ◽

pp. 755-761 ◽

Cited By ~ 14

Author(s):

Emily H. Castellanos ◽

Leora Horn

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Treatment Options ◽

Small Cell ◽

Line Treatment ◽

Second Line ◽

Small Cell Lung ◽

A Patient With Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib

Journal of the National Comprehensive Cancer Network ◽

10.6004/jnccn.2013.0054 ◽

2013 ◽

Vol 11 (4) ◽

pp. 389-394 ◽

Cited By ~ 11

Author(s):

Jonathan W. Riess ◽

Seema Nagpal ◽

Joel W. Neal ◽

Heather A. Wakelee

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Leptomeningeal Carcinomatosis ◽

Small Cell ◽

Targeted Treatment ◽

Small Cell Lung ◽